Skip to content

The analysis of the clinicopathological characteristics of sessile serrated lesions

The analysis of the clinicopathological characteristics of sessile serrated lesions

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500107255
Enrollment
Unknown
Registered
2025-08-07
Start date
2025-08-15
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sessile Serrated Lesions

Interventions

The SSLs group:None
The SSLs with dysplasia group:None

Sponsors

The Second Hospital of Shandong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. The full colonoscopy was complete; 2. The patient was detected with polyps by colonoscopy and was pathologically diagnosed as SSL.

Exclusion criteria

Exclusion criteria: 1. The patient also has other intestinal diseases: inflammatory bowel disease, hereditary colorectal cancer (the first type is non-polyposis syndrome, including Lynch syndrome and familial colorectal cancer X Lynch syndrome; The second category is polyposis syndrome, including familial adenomatous polyposis, etc. ; 2. The patient was diagnosed with a history of colorectal malignant tumors and malignant tumors in other parts before microscopic examination; 3. The patient has a history of colorectal resection and advanced adenoma resection; 4. The colonoscopy of the patient was incomplete, failing to reach the cecum, and the intestinal preparation was unqualified (Boston score <6 points).

Design outcomes

Primary

MeasureTime frame
Endoscopic data;Pathological data;Endoscopic treatment methods;Multi-omics;

Countries

China

Contacts

Public ContactShuai LI

The Second Hospital, Cheeloo College of Medicine, Shandong University

15153119050@163.com+86 176 6008 0706

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026